Advice
following a full submission:
idarucizumab (Praxbind®) is accepted for use within NHS Scotland.
Indication under review: idarucizumab is a specific reversal agent for dabigatran and is indicated in adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
In a phase III, non-randomised, case series study, treatment with idarucizumab reversed the effect of dabigatran, with a median maximum percentage reversal of 100%.
Download detailed advice179KB (PDF)
Medicine details
- Medicine name:
- idarucizumab (Praxbind)
- SMC ID:
- 1178/16
- Indication:
- Idarucizumab is a specific reversal agent for dabigatran and is indicated in adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 September 2016